References
- Tempfer CB, Reiner E, Hefler LA, Huber JC, Muendlein A. DNA microarray-based analysis of single nucleotide polymorphisms may be useful for assessing the risks and benefits of hormone therapy. Menopause 2004;82:132–7
- Peeyananjarassri K, Baber R. Effects of low-dose hormone therapy on menopausal symptoms, bone density, endometrium and cardiovascular system: a review of randomized clinical trials. Climacteric 2005;8:00
- Cushman M, KuIler LH, Prentice R, et al. for the Women's Health Investigators Investigators. Estrogen plus progestin and risk of venous thrombosis. J Am Med Assoc 2004;292:1573–80
- Anttila T, Helkala E-L, Viitanen M, et al. Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: a prospective population based study. Br Med Assoc 2004;329:539–45
- Weisberg E, Ayton R, Darling G, et al. En-dometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:83 — 92
- Smith NL, Heckbert SR, Lemaitre RN, et al. Esterified estrogen and conjugated equine estro-gens and the risk of venous thrombosis. J Am Med Assoc 2004;292:1581–7
- MacLennan AH, Sturdee DW. Time for new long-term trials of postmenopausal hormone therapies! Climacteric 2003;6:265–7
- Brownley KA, Hinderliter AL, West SG, et al. Cardiovascular effects of 6 months of hormone replacement therapy versus placebo: differences associated with years since menopause. Am J Obstet Gynecol 2004;190:1052–8
- Harman SM, Brinton E, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005;8:3 — 12
- Shaw LJ, Raggi P, Schisterman E, et al. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology 2003;228: 826–33